{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:41:51Z","timestamp":1759333311700},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2005,6,4]],"date-time":"2005-06-04T00:00:00Z","timestamp":1117843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1007\/s00259-005-1770-7","type":"journal-article","created":{"date-parts":[[2005,6,6]],"date-time":"2005-06-06T14:30:01Z","timestamp":1118068201000},"page":"1225-1233","source":"Crossref","is-referenced-by-count":16,"title":["Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin\u2019s lymphoma: initial experience"],"prefix":"10.1007","volume":"32","author":[{"given":"Maren","family":"Bienert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Reisinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Srock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice I","family":"Humplik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Reim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kroessin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Avril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pezzutto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter L","family":"Munz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,6,4]]},"reference":[{"key":"1770_CR1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM199304083281409","volume":"328","author":"JO Armitage","year":"1993","unstructured":"Armitage JO. Treatment of non-Hodgkin\u2019s lymphoma. N Engl J Med 1993;328:1023\u201330.","journal-title":"N Engl J Med"},{"key":"1770_CR2","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","volume":"4","author":"CJ Gallagher","year":"1986","unstructured":"Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4:1470\u201380.","journal-title":"J Clin Oncol"},{"key":"1770_CR3","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825\u201333.","journal-title":"J Clin Oncol"},{"key":"1770_CR4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","volume":"17","author":"MS Czuczman","year":"1999","unstructured":"Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268\u201376.","journal-title":"J Clin Oncol"},{"key":"1770_CR5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.0902-4441.2004.00171.x","volume":"72","author":"A Olivieri","year":"2004","unstructured":"Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 2004;72:10\u20137.","journal-title":"Eur J Haematol"},{"key":"1770_CR6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1470-2045(04)01490-1","volume":"5","author":"BT Hennessy","year":"2004","unstructured":"Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol 2004;5:341\u201353.","journal-title":"Lancet Oncol"},{"key":"1770_CR7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1523-5394.1998.006003195.x","volume":"6","author":"SD Scott","year":"1998","unstructured":"Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin\u2019s lymphoma. Cancer Pract 1998;6:195\u20137.","journal-title":"Cancer Pract"},{"key":"1770_CR8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"key":"1770_CR9","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.1989.7.8.1027","volume":"7","author":"OW Press","year":"1989","unstructured":"Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, et al. Treatment of refractory non-Hodgkin\u2019s lymphoma with radiolabelled MB-1 (anti-CD37) antibody. J Clin Oncol 1989;7:1027\u201338.","journal-title":"J Clin Oncol"},{"key":"1770_CR10","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.1992.10.11.1696","volume":"10","author":"MS Kaminski","year":"1992","unstructured":"Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labelled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992;10:1696\u2013711.","journal-title":"J Clin Oncol"},{"key":"1770_CR11","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","volume":"329","author":"OW Press","year":"1993","unstructured":"Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al. Radiolabelled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219\u201324.","journal-title":"N Engl J Med"},{"key":"1770_CR12","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labelled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 2002;20:2453\u201363.","journal-title":"J Clin Oncol"},{"key":"1770_CR13","first-page":"3304s","volume":"5","author":"TM Behr","year":"1999","unstructured":"Behr TM, Wormann B, Gramatzki M, Riggert J, Gratz S, Behe M, et al. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res 1999;5:3304s\u201314s.","journal-title":"Clin Cancer Res"},{"key":"1770_CR14","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/cncr.10307","volume":"94","author":"TM Behr","year":"2002","unstructured":"Behr TM, Griesinger F, Riggert J, Gratz S, Behe M, Kaufmann CC, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labelled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002;94:1363\u201372.","journal-title":"Cancer"},{"key":"1770_CR15","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00259-002-0820-7","volume":"29","author":"K Scheidhauer","year":"2002","unstructured":"Scheidhauer K, Wolf I, Baumgartl HJ, Von Schilling C, Schmidt B, Reidel G, et al. Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin\u2019s lymphoma. Eur J Nucl Med Mol Imaging 2002;29:1276\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1770_CR16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1089\/108497803322287583","volume":"18","author":"JH Turner","year":"2003","unstructured":"Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. 131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin\u2019s lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabelled in a hospital. Cancer Biother Radiopharm 2003;18:513\u201324.","journal-title":"Cancer Biother Radiopharm"},{"key":"1770_CR17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1055\/s-0038-1625644","volume":"41","author":"TM Behr","year":"2002","unstructured":"Behr TM, Gotthardt M, Becker W, Behe M. Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy. A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Gottingen\/Marburg experience. Nuklearmedizin 2002;41:71\u20139.","journal-title":"Nuklearmedizin"},{"key":"1770_CR18","first-page":"84","volume":"31","author":"RL Wahl","year":"1990","unstructured":"Wahl RL, Wissing J, del Rosario R, Zasadny KR. Inhibition of autoradiolysis of radiolabelled monoclonal antibodies by cryopreservation. J Nucl Med 1990;31:84\u20139.","journal-title":"J Nucl Med"},{"key":"1770_CR19","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.","journal-title":"J Clin Oncol"},{"key":"1770_CR20","first-page":"21s","volume":"39","author":"RL Wahl","year":"1998","unstructured":"Wahl RL, Zasadny KR, MacFarlane D, Francis IR, Ross CW, Estes J, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med 1998;39:21S\u201327S.","journal-title":"J Nucl Med"},{"key":"1770_CR21","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","volume":"14","author":"MS Kaminski","year":"1996","unstructured":"Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974\u201381.","journal-title":"J Clin Oncol"},{"key":"1770_CR22","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","volume":"96","author":"MS Kaminski","year":"2000","unstructured":"Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259\u201366.","journal-title":"Blood"},{"key":"1770_CR23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","volume":"21","author":"TE Witzig","year":"2003","unstructured":"Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol 2003;21:1263\u201370.","journal-title":"J Clin Oncol"},{"key":"1770_CR24","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s002590000276","volume":"27","author":"GA Wiseman","year":"2000","unstructured":"Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I\/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin\u2019s lymphoma. Eur J Nucl Med 2000;27:766\u201377.","journal-title":"Eur J Nucl Med"},{"key":"1770_CR25","first-page":"3281s","volume":"5","author":"GA Wiseman","year":"1999","unstructured":"Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanouilides C, Raubitschek A, et al. Radioimmunotherapy of relapsed non-Hodgkin\u2019s lymphoma with zevalin, a 90Y-labelled anti-CD20 monoclonal antibody. Clin Cancer Res 1999;5:3281s\u20136s.","journal-title":"Clin Cancer Res"},{"key":"1770_CR26","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma. J Clin Oncol 2002;20:3262\u20139.","journal-title":"J Clin Oncol"},{"key":"1770_CR27","first-page":"58","volume":"26","author":"OW Press","year":"1999","unstructured":"Press OW. Radiolabelled antibody therapy of B-cell lymphomas. Semin Oncol 1999;26:58\u201365.","journal-title":"Semin Oncol"},{"key":"1770_CR28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00262-002-0348-5","volume":"52","author":"DM Goldenberg","year":"2003","unstructured":"Goldenberg DM. Advancing role of radiolabelled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003;52:281\u201396.","journal-title":"Cancer Immunol Immunother"},{"key":"1770_CR29","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","volume":"17","author":"TE Witzig","year":"1999","unstructured":"Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 1999;17:3793\u2013803.","journal-title":"J Clin Oncol"},{"key":"1770_CR30","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","volume":"15","author":"Y Bastion","year":"1997","unstructured":"Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997;15:1587\u201394.","journal-title":"J Clin Oncol"},{"key":"1770_CR31","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.1998.16.10.3246","volume":"16","author":"GL DeNardo","year":"1998","unstructured":"DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, et al. Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin\u2019s lymphoma. J Clin Oncol 1998;16:3246\u201356.","journal-title":"J Clin Oncol"},{"key":"1770_CR32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1006\/clim.2001.5050","volume":"100","author":"T Nordoy","year":"2001","unstructured":"Nordoy T, Kolstad A, Tuck MK, Aaberge IS, Husebekk A, Kaminski MS. Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin\u2019s B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens. Clin Immunol 2001;100:40\u20138.","journal-title":"Clin Immunol"},{"key":"1770_CR33","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(95)92225-3","volume":"346","author":"OW Press","year":"1995","unstructured":"Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995;346:336\u201340.","journal-title":"Lancet"},{"key":"1770_CR34","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1998.16.10.3270","volume":"16","author":"SY Liu","year":"1998","unstructured":"Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labelled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998;16:3270\u20138.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-005-1770-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-005-1770-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-005-1770-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T15:18:48Z","timestamp":1586272728000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-005-1770-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,4]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["1770"],"URL":"https:\/\/doi.org\/10.1007\/s00259-005-1770-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,4]]}}}